PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
The lupus therapeutics market is dominated by generics and GlaxoSmithKlines Benlysta is the only drug that has gained marketing approval for SLE in more than 50 years. Following Benlystas launch, patients uptake has remained low, but due to its associated high price-tag Benlysta has managed to grow the lupus market in terms of value and is currently the top-selling drug in this market, having generated approximately $265.6m in 2014 in the seven major markets. There is high R&D activity for...
View full press release